Intersect Ent Inc
F:7IN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (18.7), the stock would be worth €-30.01 (211% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.8 | €27 |
0%
|
| Industry Average | 18.7 | €-30.01 |
-211%
|
| Country Average | 16.7 | €-26.8 |
-199%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
Intersect Ent Inc
F:7IN
|
912.9m EUR | -16.8 | -6.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 16.9 | 25.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 55 | 60.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 27.4 | 39.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 17.3 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 23.3 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 16.1 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 27 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 39.3 | 43.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 17.8 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 18.9 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Intersect Ent Inc
Glance View
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
